Drugs / PF-07899895
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06137729 | Nov 2023 → Oct 2025 | — | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07899895 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06137729 ↗ |
| Route | Oral | “Participants will receive oral ascending doses.” NCT06137729 ↗ |